Can anti-VEGF agents act as effective prophylactic treatment for diabetic patients with a high risk of developing diabetic eye disease? Data from the Protocol W’s 2-year timepoint shared at the 2021 AAO Annual meeting might provide some answers on that question. Raj Maturi, MD, joined New Retina Radio to discuss his podium presentation on the topic. 

New Retina Radio also invited Usha Chakravarthy, MD, PhD, to the program to outline her presentation on the secondary endpoints of the EDNA study. What was found when a team closely monitored patients for progression of unilateral to bilateral wet AMD? Join us on this episode to hear the details from these two presentations. 

This editorially independent podcast is supported with advertising.